Transcript 02_IBM_Overview_20090922

German CDISC User Group Meeting
IBM Intro
September 22nd, 2009
© 2009 IBM Corporation
IBM‘s R&D Team @German CDISC User Group
© 2009 IBM Corporation
Creating Pharmaceutical Break-Throughs:
- We believe there is no one magic bullet …
 It takes a variety of
data sources, ‘best
of breed’ tools &
technologies to
really create
break-throughs
… but one open & harmonized data-standard would help
3
IBM
© 2009 IBM Corporation
A real life example taken from PoC on
Hepatotoxic AE & CYP450 Marker
Clinical Data
Management
Lab Data
SAS,
PL/SQL
Safety
Study 4712
Pre-clin stud
Coding
This now needs to be confirmed by a
statistician in a compliant manner, but
hopefully a marker was found
Query
Management
Study 4711
Study 4712
Study 0816
Clinical
Research
Organizations
Clinical Trial
Management
Oracle LSH
Statistical
Programming
Registries
Study 0815
Patient
Diaries
Electronic
Data
Capture
DDQB
Genomic data

Combining the search with Genomic
data of the patients finally led to signal
4
IBM
Spotfire
Med. Pub. As PDF-files
© 2009 IBM Corporation
Life Sciences Pharma R&D - Services Portfolio
 Focused R&D services
– R&D Strategy & Process Optimization
– Clinical Data Integration & Aggregation (CDA)
– Clinical Trial (CTMS) and Investigator Relationship Management (IRTM)
– Electronic Data Capture (EDC)
– Integrated Project Resource and Portfolio Management (IPRM)
– Solutions for Compliance in Regulated Environments (Score)
 (e.g. Submission management, content management, clinical portal, …)
– Chemsearch Patent Data-Base
– Biobank Support & Pharmacogenomics (PGx)
– Data Driven Drug discovery (4D)
 Modelling and Simulation
 Data Mining, Web Mining, Text Mining, Target finder
 Other services applicable to R&D
– Pervasive computing
– Petaflop and Grid Computing
– Process Analytical Technologies (PAT)
– Training & Knowledge Management
– Computer System Validation (CSV)
© 2009 IBM Corporation
IBM’s Deep Industry Knowledge
– the R&D Group Embedded in the Larger Picture
IBM’s consulting capabilities are built around specific strategic and operational challenges facing pharmaceutical
companies in the evolving global marketplace. With more than 1000 pharmaceutical industry specialists around the
world, IBM Life Sciences consulting practice is part of the world’s largest consultant services organization with
significant depth and breadth of industry experience.
World-Wide Industry Specialist Resources:
Pharmaceutical Practice consists of > 2.000 industry specialists worldwide
Manufacturing Operations
 Materials & Product Flow
Management
 New Product/Package Introductions
in Operations
 Clinical Supply Chain Process
 Contract Manufacturing
 Regulatory Compliance & Validation
 Supply Chain Information
Management
Business Planning & Development
 Business Plan Development
 Strategy Valuation
 Strategy & Planning
 Competitive Positioning
 Due Diligence
 Mergers & Acquisitions
Research & Development
 Discovery/Pre-Clinical
 Clinical Development
 Clinical Data Aggregation
 Regulatory Compliance
 Pharmacovigilance
 Process Optimization
Sales
 Account Management
 Health Care & Government Contract
Management
 Sales Operations Improvement
 Field Sales Management
 Sales Force Automation
Information Management
 Management Information Systems
 Knowledge & Information
Management
 Structured Product Labeling
 Drug submission
Marketing
 Product Marketing
 Reimbursement Strategy
 DTC Strategy
 Rx-to-OTC switching
 Strategic Pricing
Financial Management
 Shared Services
 Performance Management
 Financial System Management &
Reporting
© 2009 IBM Corporation
In a Word, IBM Stands for PROGRESS
IBM is a values-based enterprise of individuals
who create and apply technology to make
the world
work better.
Today, about 400,000 IBMers around the world invent and
integrate hardware,
software and services to help
forward-thinking enterprises, institutions and people
everywhere succeed on a smarter planet.
© 2009 IBM Corporation
IBM - Major Businesses
Global
Business
Services
Provides professional
services and application
outsourcing services
Software
Provides middleware that enables clients to
integrate systems, processes and applications,
as well as computer operating systems
Global
Technology
Services
Provides outsourced IT
infrastructure services and
business process services
Global
Financing
Provides financing solutions that can be
customized to address specific IT needs,
from competitive rates to flexible payment
plans and loans
Systems
and
Technology
Provides advanced
computing, storage and
semiconductor technology
and products
S&D
and
Research
Our Sales and Research, Development
and Intellectual Property organizations
provide a wide spectrum of client support
and additional value
© 2009 IBM Corporation
A Leader in Technology
IBM maintains the world’s largest private-sector
research arm. In 2008, for the 16th consecutive
year, IBM was issued more U.S. patents (4,186)
than any other company.
In the last six years IBM has aggressively
complemented an investment of $35 billion in
research and development with more than
100 acquisitions of hardware, services and
software companies.
© 2009 IBM Corporation
http://www.research.ibm.com/FunGen/FGDownloads.htm
Genes@Work
Gene expression analysis
microarray 1
microarray 2
microarray 3
...
A software environment for
gene expression analysis and
machine learning
....................
gene Ng
gene 3
gene 2
gene 1
Genes@Work
microarray Ne
pattern
Njk(j,k,Ne,Ng,) ~
Ng
k
Ne k
Ng-k
Ne-j
 (1-
[1-(1+j-1 )k k ]
j
( )( )
 = j
j-1
j
-(j-1)
p = 1-exp{-Njk}
Lepre, Rice, Tu, and Stolovitzky, “Genes@Work: an efficient algorithm for pattern discovery and multivariate feature
selection in gene expression data”, Bioinformatics 20(7):1033-44 (2004).
Other Selected Relevant Papers:
Mateos, Dopazo, Jansen, Tu, Gerstein and Stolovitzky, “Systematic learning of gene functional classes from DNA
array expression data by using multilayer perceptrons”, Genome Research 12, 1703-15 (2002).
Califano, Stolovitzky and Tu, “Analysis of Gene Expression Microarrays for Phenotype Classification” , Proceedings
of the 8th Annual Intelligent Systems in Molecular Biology (ISMB) 2000; 8:75-85 (2000).
© 2009 IBM Corporation
Functional Genomics & Systems Biology Group
The DREAM Project
 DREAM (Dialogue on Reverse Engineering Analysis and
Methods) aspires to collect data and techniques that
researchers can use to understand how well their reverse
engineering methods can infer the nature of the underlying
biochemical networks in the cell.
 Ideally, researchers would like to test their techniques on a
"gold standard" biological network, where interactions are
perfectly known.
 Such networks are often artificial, may lack features found in
real biological networks, and may include wrong and missing
interactions.
 Unlike most current approaches, the deepest biological
insight will come from combining different types of
information, including data on gene expression, proteins,
and small molecules, among others.
Robustness,
sparceness
Reverse
Engineering
Acetyl-CoA
Malate
CoA
Oxaloacetate
MDH2
MLS1
Citrate
CIT2
ICL2
Glyoxylate
Fumarate
Isocitrate
CoA Acetyl-CoA
Data Mining
Fumarate
Succinate
Tricarboxylic Acid Cycle
Succinyl-CoA
Ketoglutarate
Glyoxylate Cycle
Simulation
Prediction and
experimental
design
© 2009 IBM Corporation
© 2009 IBM Corporation
Computational Chemistry
and applications in Biochemistry
IBM help enhance your modeling & simulation framework for design of pharmaceutical products:
–
simulates complex enzymatic reactions (ADMET projects or enzyme engineering in general);
–
model ligand-protein interaction at the stage of lead identification and optimization.
Examples of systems under investigation are:
–
metal-activated enzymatic reactions and design of novel materials for organic electronics
–
ligand-protein interaction, such as HIV-protease inhibitors and simulating how progesterone interacts with its receptor in
the human body;
–
identifying molecules responsible for the degradation of flavor in foods.
Method used:
–
combined quantum mechanics/molecular mechanics (QM/MM),
–
classical molecular dynamics using quantum-refined force-fields.
This activity involves diverse technical steps:
•development of new algorithms
•code optimization, particularly for massive parallel computing, eg CPMD (Power, PowerLinux and Blue Gene/L.
•data analysis
•selected applications aimed at unraveling the physics and chemistry of the system
•virtual design of novel materials for advanced technologies
•development of interfaces for Grid computing.
During the past 10 years IBM established scientific collaborations with a number of industrial labs.
Contact: Wanda Andreoni & Alessandro Curioni, IBM Zurich Research Labs
© 2009 IBM Corporation
© 2009 IBM Corporation
Fighting AIDS virus

IBM and University of Edinburgh use World's most advanced supercomputer
combined with lab experiments to speed the design of drugs aimed at inhibiting
infection by the HIV virus.

The project is focused on how the human HIV-1 virus attaches to cells in the body
and injects its genetic material and to speed the design of inhibitors for the part of
the virus responsible for allowing the virus' genetic material to enter the human cell

In 2007, IBM's Haifa Research Laboratories and some European partners developed
an integrated system for anti-HIV treatment called EuResist. Enabled by the
integration of comprehensive databases, advanced data analytics and prediction
tools, the system can forecast how genetic HIV variants will respond to specific
antiretroviral treatments. It can therefore help doctors to choose the most effective
drugs and drug combinations for their HIV patients
© 2009 IBM Corporation
Scripps Research Institute and IBM Partner Tackle the Global
Pandemic Challenge
 Conduct advanced research on pandemic viruses

Goals Include
1. Develop a means to anticipate, manage and contain
infectious diseases
2. Leverage Scripps world class research and IBM’s expertise
in computational biology and supercomputing
3. Attract advanced research talent to the state of Florida
through collaborations associated with the pandemic work

Components of Collaboration
1. Exploit an IBM Blue Gene supercomputer to conduct
advanced disease modeling
2. Provide access to talent and resources of IBM’s
Computational Biology Center
Have a look at www.ibm.com/avianflu
© 2009 IBM Corporation
Building Multiscale Heart Models (1/2)
Heart disease is the leading killer in the developed world
Heart will allow better therapies for heart disease…
...but will require bridging between organ level and molecular level
Organ level
Reconstruction of
whole heart by
Peter Hunter, U. of
Auckland
Cell level
In each cell of heart, a
lattice of sarcomeres
produce contraction on
every heart beat.
Molecular level
Sarcomere contracts by
cyclical interactions of
myosin on thick filament
(red) and actin in thin
filament (green).
Collaborators - University of Auckland, JHU, Loyola, UCSD, UIC, Oxford, others
© 2009 IBM Corporation
FDA’s JANUS Submission Data Repository Model – by IBM
Current
Clinical
Study
Past
Clinical
Studies
JANUS
 Grew out of CDISC and HL7 data standardization efforts
 FDA and IBM designed the JANUS clinical data submission repository
–
Worked under a Cooperative R&D Agreement (CRADA), completed in 2004
–
JANUS logical data model published: http://www.fda.gov/oc/datacouncil/
 IBM implemented a JANUS prototype for FDA and NCI
–
FDA and NCI cooperating through an Interagency Operational Task Force (IOTF)
–
Testing completed in January 2006
 IBM is currently implementing a JANUS Operational Prototype for FDA and
NCI
© 2009 IBM Corporation
Leading the Transition to a Smarter Planet
Today, IBM is helping our clients to change
the way the world
literally works – and to make the planet not just smaller and
“flatter,” but smarter. IBM is applying its expertise, global scope
and creativity to build the backbone of 21st century industries and
public institutions.
Our world is becoming
INSTRUMENTED
Our world is becoming
INTERCONNECTED
Virtually all things, processes and ways of working are becoming
INTELLIGENT
© 2009 IBM Corporation
Building a Smarter Planet
Smarter R&D
+
Intelligent
+
Instrumented
=
Interconnected
An opportunity for life sciences organizations
to think and act in new ways.
© 2009 IBM Corporation